These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 2146103)
1. Chronic chloroquine treatment enhances insulin release in rats. Asamoah KA; Robb DA; Furman BL Diabetes Res Clin Pract; 1990 Jul; 9(3):273-8. PubMed ID: 2146103 [TBL] [Abstract][Full Text] [Related]
2. Comparison of beta-cell function after long-term treatment with either insulin, insulin plus gliclazide or gliclazide in neonatal streptozotocin-induced non-insulin-dependent diabetic rats. Kawai K; Suzuki S; Murayama Y; Watanabe Y; Yamashita K Diabetes Res Clin Pract; 1991 Jul; 12(3):163-72. PubMed ID: 1832376 [TBL] [Abstract][Full Text] [Related]
3. Long-term gliclazide treatment improves the in vitro glucose-induced insulin release in rats with type 2 (non-insulin-dependent) diabetes induced by neonatal streptozotocin. Serradas P; Bailbé D; Portha B Diabetologia; 1989 Aug; 32(8):577-84. PubMed ID: 2528491 [TBL] [Abstract][Full Text] [Related]
4. Protective effect of 4,6-O-ethylidene glucose against the cytotoxicity of streptozotocin in pancreatic beta cells in vivo: indirect evidence for the presence of a glucose transporter in beta cells. Kawada J; Okita M; Nishida M; Yoshimura Y; Toyooka K; Kubota S J Endocrinol; 1987 Mar; 112(3):375-8. PubMed ID: 2951476 [TBL] [Abstract][Full Text] [Related]
5. S-methyl-L-thiocitrulline counteracts interleukin 1 beta induced suppression of pancreatic islet function in vitro, but does not protect against multiple low-dose streptozotocin-induced diabetes in vivo. Sternesjö J; Welsh N; Sandler S Cytokine; 1997 May; 9(5):352-9. PubMed ID: 9195135 [TBL] [Abstract][Full Text] [Related]
6. Effect of cerebrocrast, a new long-acting compound on blood glucose and insulin levels in rats when administered before and after STZ-induced diabetes mellitus. Briede J; Stivrina M; Stoldere Dz; Vigante B; Duburs G Cell Biochem Funct; 2007; 25(6):673-80. PubMed ID: 16986170 [TBL] [Abstract][Full Text] [Related]
7. Transgenic mice expressing Shb adaptor protein under the control of rat insulin promoter exhibit altered viability of pancreatic islet cells. Welsh M; Christmansson L; Karlsson T; Sandler S; Welsh N Mol Med; 1999 Mar; 5(3):169-80. PubMed ID: 10404514 [TBL] [Abstract][Full Text] [Related]
8. Distinct glucose lowering and beta cell protective effects of vanadium and food restriction in streptozotocin-diabetes. Cam MC; Rodrigues B; McNeill JH Eur J Endocrinol; 1999 Nov; 141(5):546-54. PubMed ID: 10576774 [TBL] [Abstract][Full Text] [Related]
9. Attenuation of streptozotocin-induced diabetes in rats by pretreatment with chloroquine. Asamoah KA; Furman BL; Robb DA Clin Sci (Lond); 1989 Feb; 76(2):137-41. PubMed ID: 2647363 [TBL] [Abstract][Full Text] [Related]
10. Cholecystokinin octapeptide: a potential growth factor for pancreatic beta cells in diabetic rats. Kuntz E; Pinget M; Damgé P JOP; 2004 Nov; 5(6):464-75. PubMed ID: 15536283 [TBL] [Abstract][Full Text] [Related]
11. Prevention of hyperglycemia improves the long-term result of islet transplantation in streptozotocin-diabetic rats. Ar'Rajab A; Ahrén B Pancreas; 1992; 7(4):435-42. PubMed ID: 1386465 [TBL] [Abstract][Full Text] [Related]
12. Glucagon-like peptide-1(7-36)-amide confers glucose sensitivity to previously glucose-incompetent beta-cells in diabetic rats: in vivo and in vitro studies. Dachicourt N; Serradas P; Bailbé D; Kergoat M; Doaré L; Portha B J Endocrinol; 1997 Nov; 155(2):369-76. PubMed ID: 9415071 [TBL] [Abstract][Full Text] [Related]
13. Protection against streptozotocin-induced diabetes by superoxide dismutase. Robbins MJ; Sharp RA; Slonim AE; Burr IM Diabetologia; 1980 Jan; 18(1):55-8. PubMed ID: 6444904 [TBL] [Abstract][Full Text] [Related]
15. Effect of 1-[4- [2-(4-bromobenzenesulfonamino) ethyl] phenylsulfonyl]-3-(trans-4-methylcyclohexyl)urea (I4), a new synthetic sulfonylurea compound, on glucose metabolism in vivo and in vitro. Wu GZ; Hong G; Zhang WP; Zhang HB Arzneimittelforschung; 2009; 59(11):550-6. PubMed ID: 20066963 [TBL] [Abstract][Full Text] [Related]
16. Long-term changes in the diabetic state induced by different doses of streptozotocin in rats. Tancrède G; Rousseau-Migneron S; Nadeau A Br J Exp Pathol; 1983 Apr; 64(2):117-23. PubMed ID: 6221747 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of phosphodiesterase 3B in insulin-secreting cells of normal and streptozocin-nicotinamide-induced diabetic rats: implications for insulin secretion. Zywert A; Szkudelska K; Szkudelski T J Physiol Pharmacol; 2014 Jun; 65(3):425-33. PubMed ID: 24930515 [TBL] [Abstract][Full Text] [Related]
18. Protective effect of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthetase, against streptozotocin-induced diabetes. Masiello P; Cubeddu TL; Frosina G; Bergamini E Diabetologia; 1985 Sep; 28(9):683-6. PubMed ID: 2933287 [TBL] [Abstract][Full Text] [Related]
19. Lisofylline, a novel anti-inflammatory agent, enhances glucose-stimulated insulin secretion in vivo and in vitro: studies in prediabetic and normal rats. Striffler JS; Nadler JL Metabolism; 2004 Mar; 53(3):290-6. PubMed ID: 15015139 [TBL] [Abstract][Full Text] [Related]
20. Effects of the amino-terminal portion of human growth hormone on glucose clearance and metabolism in normal, diabetic, hypophysectomized, and diabetic-hypophysectomized rats. Salem MA Endocrinology; 1988 Sep; 123(3):1565-76. PubMed ID: 3042372 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]